Skip to main content

Advertisement

Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management

Cardiovascular Diabetologyvolume 18, Article number: 54 (2019) | Download Citation

Abstract

With an increasing global burden of coronary artery disease (CAD), early detection and timely management of risk factors are crucial to reduce morbidity and mortality in such patients. Diabetes mellitus (DM) is considered an independent risk factor for the development of CAD. Metformin, an anti-diabetic drug, has been shown in pre-clinical and clinical studies, to lower the cardiovascular events in the DM patients. Growing evidence suggests that metformin has a protective effect on coronary artery beyond its hypoglycemic effects. Given its global availability, route of administration and cost, metformin provides an alternate/additional therapeutic option for primary and secondary prevention of CAD in DM and non-diabetics alike. Future prospective cohort-based studies and randomized clinical trials are needed to identify ‘at-risk’ population who may potentially benefit from metformin.

Introduction

Coronary artery disease (CAD) is among the leading cause of mortality and morbidity worldwide and puts an enormous economic burden in the society [1]. There are multiple risk factors of CAD like tobacco, obesity, hypertension and high blood cholesterol [2]. Diabetes mellitus (DM) is considered to be an independent risk factor in the development of CAD [3]. Macrovascular complications of DM, involving the cardiovascular system, constitute the leading cause of death in longstanding diabetics [4,5,6]. Metformin, a prominent biguanide class of drugs, controls the level of blood glucose in the body through lowering of the peripheral insulin resistance and concurrent decrease in intestinal absorption of glucose [7]. Current treatment guidelines recommend the use of metformin as a first-line therapy for patients with DM [8]. While primarily used as an anti-diabetic drug, other pleiotropic effects of metformin remained largely unexplored. Burgeoning evidence points towards the cardioprotective effects of metformin in its improvement of cardiovascular outcomes in patients with well-defined risk factors. Although clinical trials conducted on diabetic patients clearly demonstrated the therapeutic potential of metformin in reducing cardiovascular mortality and morbidity in DM patients [9], their beneficial effects in non-diabetic patients remain unclear. The cardioprotective effect of metformin in DM patients can be attributed to its anti-atherosclerotic property. In this article, we review the existing literature reporting the anti-atherosclerotic property of metformin in the cardiovascular space (Fig. 1).

Fig. 1
figure1

Beneficial pleiotropic effects of metformin on cardiovascular and the potential mechanisms. SREBP sterol regulatory element-binding proteins, ABCA1 ATP-binding cassette transporter A1, AMPK AMP-activated protein kinase, NO nitric oxide, ER endoplasmic reticulum, HDL high-density lipoprotein

Full size image

Cardiovascular effects of metformin: clinical scenario

Metformin in diabetes mellitus (DM)

Type 2 diabetes mellitus (T2DM) is considered as an independent risk factor for the development of CAD [10]. Therefore, tight blood glucose control is critical to limit the mortality and morbidity from CVD in T2DM patients. Metformin, a first line anti-diabetic drug, has been reported to reduce major cardiovascular events associated with atherosclerotic cardiovascular disease (ASCVD) in T2DM patients or improve the surrogate endpoints of ASCVD such as carotid intima-media thickness (CIMT). A landmark study in this area was the UK Protective Diabetes Study (UKPDS) [11], which randomized 1704 overweight (> 120% ideal body weight) patients with newly diagnosed T2DM to receive conventional treatment with diet alone in one trial arm or either metformin, sulphonylurea, or insulin in the other. After a median follow up of 10.7 years, the metformin group had a 36% lower all-cause mortality (P = 0.011) and a concurrent a 39% lower risk (P = 0.011) in the incidence of myocardial infarction than the conventional treatment group but did not differ significantly from the other intensive glucose control treatment group. However, in a combined analysis of a supplementary of the same clinical trial, where 537 non-overweight and overweight patients with uncontrolled plasma blood glucose (6.1–15.0 mmol/L) were treated with sulfonylureas with and without metformin, the effect of metformin on cardiovascular outcomes was not statistically significant. A possible explanation of this phenomenon could be related to the beneficial effect of tight glycemic control from metformin that prevented future cardiovascular consequences. Subsequent follow-up study of 10 years after UKPDS, however, reported continuous risk reduction of myocardial infarction (33%, P = 0.005) in patients treated with metformin despite no changes in the glycated hemoglobin (HbA1c) levels [12]. Since no new glucose-lowering therapy was introduced in the study cohort during this period, the results highlight the beneficial cardiovascular effects of metformin. This effect of metformin was particularly pronounced among overweight patients after a long duration of follow-up. In a continued effort to study the add-on effects of metformin on macrovascular or microvascular disease in insulin-treated T2DM patients, Kooy et al. [13] randomized 390 T2DM patients, with a mean age of 53 years, to receive metformin (850 mg/day) or placebo and followed them for 4.3 years. The results show that metformin treatment significantly improved the macrovascular end point compared with placebo (HR 0.61, 95% CI 0.40–0.94, P = 0.02), which could not be explained solely by the difference in weight and metformin-associated changes in metabolic or hemodynamic variables, such as HbA1C level [13]. Further study by Katakami et al. [14] in a cohort of 118 patients with T2DM who were randomized to receive glibenclamide (n = 59), gliclazide (n = 30), glibenclamide plus metformin (n = 29), with a median follow-up duration of 3 years, also showed that the CIMT in glibenclamide plus metformin group was significantly smaller than that in the glibenclamide and gliclazide groups in univariate and multivariate regression analysis (P < 0.05). A meta-analysis of 35 clinical RCTs confirmed the cardiovascular benefits of metformin in comparison to placebo in younger population followed over a long duration [15]. Taken together, these observations strengthen the rationale behind the use of metformin in ‘at-risk’ population (T2DM patients) from a younger age to decrease cardiovascular events.

A seminal study in the field, The study on the prognosis and effect of antidiabetic drugs on type 2 diabetes mellitus with coronary artery disease (SPREAD-DIMCAD) was conducted to evaluate the major cardiovascular events and mortality among type 2 diabetic patients with CAD after their treatment with glipizide or metformin [16]. Among the 304 T2DM patients enrolled for the RCT who were followed up for 5 years, the metformin group showed a significantly lower cardiovascular endpoint (recurrent cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke or arterial revascularization by percutaneous transluminal coronary angioplasty (PTCA) or by coronary artery bypass graft, death from a cardiovascular cause) than the glipizide group (HR 0.54, 95% CI 0.30–0.90, P = 0.026). However, the glycated hemoglobin values in the two groups were similar (7.0% vs 7.1%, P > 0.05) [16]. The results were ‘proof of concept’, suggesting the pleiotropic effects of metformin in the heart and blood vessels, independent of its glucose-lowering activity.

The REversing with MetfOrmin Vascular Adverse Lesions (REMOVAL) Trial is the largest and longest double-blind placebo-controlled RCT to evaluate cardiovascular effect of metformin in adults with type 1 DM (T1DM) with a median follow up duration of 5 years in patients with high cardiovascular risk (have ≥ 3 of 10 specified cardiovascular risk factors) [17]. In REMOVAL trial, 428 insulin-treated patients were randomly assigned to metformin and placebo. At a follow-up visit, atherosclerosis progression, measured by the averaged maximal CIMT, was significantly reduced with metformin (− 0.013 mm/year, − 0.024 to − 0.003; P = 0.0093) [18], indicating possible cardiovascular benefits, but warrants further investigation. However, the significant reduction in HbA1c (− 0.13%, 95% CI − 0.22 to − 0.037; P = 0.0060) over 3 years was more robust over the initial 3-month after the commencement of treatment (− 0.24%, − 0.34 to − 0.13; P < 0.0001) [18]. In the SPREAD-DIMCAD trial, the metformin group showed a significantly lower cardiovascular endpoint with similar HbA1c level, suggesting the metformin effect is independent of blood sugar level. However, in REMOVAL trial, the reduction of CIMT was associated with HbA1c reduction with metformin. Taken together, the cardioprotective properties of metformin appears to be a consequence of its atheroprotective effect of metformin. However, the conundrum, concerning the association of the atheroprotective effect of metformin with its anti-hyperglycemic effects in T1DM patients, still remains unanswered.

Recent evidence demonstrates the synergistic effects of co-administration of metformin with other drugs. Treatment with metformin alongside empagliflozin, a new sodium glucose cotransporter-2 (SGLT2) inhibitor, has significantly improved arterial stiffness compared to metformin alone in T1DM patients [19]. The effect was higher than either combination of glitazones or alpha-glucosidase inhibitors with metformin and was also associated with lower major adverse cardiovascular events (MACE) risk in comparison to sulphonylureas and metformin combinatorial treatment in T2DM patients [20]. Metformin with Saxagliptin has been shown to improve the endothelial dysfunction in early diabetics [21] and its combination with vildagliptin is poised as a viable alternative in the treatment of T2DM and CAD due to the lower rate of recurrent cardiovascular events, in part due to its anti-inflammatory property [22]. Even, metformin with ascorbic acid has been shown to be effective in reducing risks for diabetes-related long-term complications (including albumin/creatinine ratio) [23]. However, increased BMI in metformin-exposed children during intrauterine development might confer them a higher risk of developing cardiometabolic diseases later in their adulthood [24]. Recent evidence supports the use of liraglutide as a viable alternative to metformin for recent-onset T2DM in women during their child-bearing age to circumvent such clinical scenarios [25].

Metformin in non-diabetics

Although the cardiovascular benefits with metformin are well-established in diabetic patients, their role in non-diabetic patients remains elusive. In a small randomized double-blind placebo-controlled study consisting of 33 non-diabetic women, it was shown that metformin can reduce myocardial ischemia in female patients with angina, compared to placebo [26]. However, a study by Hao et al. [9] consisting of 130 patients with dyslipidemia and obesity who were randomized to atorvastatin or atorvastatin plus metformin, showed atorvastatin combined with metformin was more effective than atorvastatin monotherapy group in improving the rate of obesity and subclinical inflammation. A subsequent study by Eduardo et al. [27] confirmed that metformin decreased the CIMT (− 0.1 mm, P = 0.04, vs − 0.02 mm, P = not significant) in comparison to control group in patients with metabolic syndrome, thereby indicating its role in cardioprotection.

However, recent studies have questioned the validity of the conclusion from prior studies. The Carotid Atherosclerosis: MEtformin for insulin ResistAnce (CAMERA) [28] study involving 173 non-diabetic patients with CAD who were on statin therapy, were assigned to either metformin or matching placebo. No improvement in CIMT was reported in the metformin group (slope difference 0.007 mm/year, P = 0.29) when compared with a placebo group, although HbA1c, insulin, and insulin resistance index decreased significantly in the metformin group (P < 0.05) [28]. The possible explanations for the conflicting outcomes in these studies can be attributed to the difference in baseline characteristics of the patients (a type of disease, age, taking other hypoglycemic and lipid-lowering drugs), study endpoints and follow-up duration of the individual clinical study. Whether metformin has a cardiovascular benefit in pre-diabetic patients is not clear. An area of active research, ongoing multicenter RCT Glucose Lowering in Non-diabetic Hyperglycemia Trial (GLINT, ISRCTN34875079) is currently enrolling non-diabetic patients for treatment with metformin to evaluate the incidence of cardiovascular death and non-fatal myocardial infarction events. The findings from this study will provide more insight in the prophylactic use of metformin in a similar cohorts.

Cardiovascular effects of metformin: translational and pre-clinical evidence

The large cache of clinical data demonstrating the cardioprotective effects of metformin warrants further mechanistic insight. Possible explanations of the cardioprotective effects of metformin can be due to its pleiotropic effects in blood vessels including endothelial cells, and smooth muscle cells, blood lipid and chronic systemic inflammation.

Anti-atherosclerotic effect of metformin

Data accrued over a period of 30 years, has shown that metformin can reduce the formation of atherosclerotic plaques in animals fed on a high cholesterol diet [29, 30]. Li et al. [30] used a high-cholesterol diet to induce atherosclerosis in rabbits and studied the anti-atherosclerotic effect of metformin. They demonstrated metformin significantly reduces atherosclerotic plaque with decreased serum high-sensitivity C-reactive protein with concurrent inhibition the of NF-κB pathway activation in the vascular wall. Recent studies have also found that metformin can reduce plaque formation in a high cholesterol diet-induced atherosclerotic Apolipoprotein E knockout (ApoE−/−) murine model [31]. Calcification of atherosclerotic plaque has been associated with plaque instability and acts a strong indicator of poor clinical cardiovascular outcomes in patients [15, 16]. Recently, Cai et al. [32] reported that metformin [100 mg/(kg day)] significantly reduced calcification of atherosclerotic plaque in ApoE−/− mice fed on a high-fat diet, suggesting that metformin may also improve plaque stability. Our prior study had also confirmed the anti-atherosclerotic property in high-cholesterol fed rabbits [33].

Vascular endothelial protection effect of metformin

Vascular endothelial dysfunction is the first step in atherosclerosis and one of the important pathological processes. Clinical studies suggest that metformin may significantly improve endothelium-dependent vasodilation in patients with T2DM and polycystic ovarian syndrome [34, 35]. In a preclinical experiment, metformin has been shown to increase NO-mediated vasodilation in endothelial cells in vitro [36]. Further studies have shown that it may increase NO production by activating AMPK pathway and thus improve vascular endothelial function [37]. Studies have also found that activation of AMPKα2 attenuates endoplasmic reticulum stress in vascular endothelial cells [38]. Metformin, being an agonist of AMPKα2, can activate AMP-activated protein kinase and protect human coronary artery endothelial cells against diabetic lipoapoptosis [39], suggesting an alternative mechanism of cardioprotective effect in the body.

Metformin and vascular smooth muscle cells

Vascular smooth muscle cells (VSMCs) proliferation, migration and phenotype conversion involved in the development of atherosclerosis [40], and calcification of VSMCs in atherosclerotic plaque is closely related to plaque instability [41]. Studies found that the activation of AMPKα2 can inhibit the abnormal migration of VSMCs, delay the intimal thickening and increase the stability of atherosclerotic plaques [42, 43]. Recent animal studies have shown that metformin can reduce the formation of calcification in VSMCs in atherosclerotic plaque through the activation of the AMPK pathway [17, 53]. Therefore, metformin may play an anti-atherosclerotic role through AMPK-mediated VSMCs regulation.

Metformin and blood lipids

LDL-C level is an important risk factor for atherosclerosis and every 38.7 mg/dL reduction of LDL-C results in a 20% reduction in cardiovascular events [44]. A possible explanation of the cardioprotective property of metformin can be explained by its effects on lowering LDL-C. An observational study reported that metformin reduces LDL-C in patients with T2DM by about 11.85 mg/dL (P < 0.05) [45]. However, multiple pre-clinical studies [18,19,20] have also reported that metformin reduce the aortic cholesterol deposition and atherosclerotic plaque formation in high cholesterol diet-induced atherosclerotic rabbit or murine models, without affecting their serum total cholesterol (TC) and LDL-C levels. Subsequently, three RCTs: the CAMERA study (baseline LDL-C level: about 108.4 mg/dL and 100% of the subjects had statins), the HOME study (baseline LDL-C level: about 137.0 mg/dL, 34% of the subjects used statins) and the SPREAD study (baseline LDL-C level of about 107.9 mg/dL and 62% of the subjects used statins) did not report any reduction of LDL-C levels with metformin [13, 16, 28]. The difference in clinical outcomes in various studies can be a consequence of the difference in baseline LDL-C levels and/or types of lipid-lowering drugs used. Not surprisingly, both HOME and SPREAD had documented the cardiovascular benefit of metformin, implying that LDL-C reduction may not be a primary contributor in its anti-atherogenic effects.

In contrast to LDL-C, high-density lipoprotein cholesterol (HDL-C) has a cardioprotective effect with HDL-C levels being inversely associated with cardiovascular events. Besides the HDL-C levels, the improvement of HDL cholesterol efflux has become a new target for the treatment of ASCVD in recent years. Previous studies indicated impaired HDL function may accelerate the development of atherosclerosis [46], and reduced HDL cholesterol efflux is associated with an increased risk of ASCVD [47]. Patients with diabetes are often associated with decreased HDL levels and impaired function [48, 49]. Of note, an RCT including 3070 people with impaired glucose tolerance reported that metformin treatment increases HDL-C levels, but the effect wears off after adjusting for body mass index weakened (P = 0.06) [50]. The HOME and CAMERA studies also yielded similar results [13, 28]. Matsuki et al. [51] also found that HDL-mediated cholesterol efflux was significantly reduced after human HDL was glycosylated, and HDL-mediated cholesterol efflux returned to normal levels after intervention with metformin in glycosylated HDL, indicating metformin may exert anti-atherosclerotic function by improving cholesterol reverse function of HDL.

Emerging studies have found that elevated triglyceride (TG) levels increase the risk of ASCVD and lower blood TG can reduce cardiovascular events [52,53,54,55]. In pre-clinical studies, metformin treatment (200 mg/kg/day) in mice for 4 weeks significantly reduced serum TG levels under high-fat diet (− 38%, P < 0.05) [56]. Further studies found that metformin did not affect the production and secretion of very low-density lipoprotein (VLDL) in the liver, but promoted the fatty acid oxidation of brown fat, which may be related to the activation of adenosine monophosphate-activated protein kinase (AMP-activated kinase, AMPK) pathway [56]. We have previously shown that metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway [57]. Apolipoprotein A5 is a novel member of the apolipoprotein family, was reported to have a strong ability to decrease serum concentrations of TG [58]. Clinical trial, HOME (metformin dosage: 850 mg/day) showed no significant difference in TG levels between metformin and placebo (0.88 mg/dL, P = 0.82) [13]. CAMERA study (metformin dosage: 1000 mg/day) also found that metformin had no significant effect on TG level (− 7.08 mg/dL, P = 0.054). However, a systematic review analyzed 41 clinical studies and found only high doge of metformin (> 1700 mg/day) decreased plasma TG significantly [59]. The negative result may due to the lower dosage used in these trials. In all, we can infer that metformin, at higher dose, could regulate TG levels and HDL function which may contribute to the anti-atherosclerotic effect.

Anti-inflammatory effects of metformin

The chronic inflammatory process leading to atherosclerosis is well-documented [60]. Previous studies showed that high-sensitivity C-reactive protein is an independent risk factor for cardiovascular disease [37]. Li et al. [30] found metformin treatment at a dose of 150 mg/kg for 16 weeks significantly reduced serum high-sensitivity C-reactive protein in high-cholesterol diet fed rabbits. A possible mechanism of this inverse correlation may be related to the inhibition of NF-κB in the vascular wall by metformin [30]. In an in vitro study, Isoda et al. [61] also found that metformin can inhibit the activation of NF-κB in endothelial cells and vascular smooth muscle cells in a concentration-dependent manner, thus inhibiting the effect of interleukin-1β-induced inflammatory cytokines secretion. The mechanism of action of metformin has also been shown to be closely related to the AMPK pathway [62]. Hattori et al. [63] found metformin inhibited the TNF-α-induced activation of NF-κB in a dose-dependent manner via activating AMPK, which was attenuated by siRNA knockdown of AMPKα1, providing a possible explanation for the anti-inflammatory effect may be related to AMPK pathway activation.

Metformin and mononuclear macrophages

Atherosclerotic plaques mainly consist of lipid-rich foam cells deposited under the intima. Mononuclear macrophages migrate to the intima, phagocytose cholesterol-containing lipids through cell membrane surface scavenger receptors and transform into foam cells. In this process, the expressions of cholesterol efflux related receptors, such as ATP-binding cassette transporter A1 (ABCA1) and G1 are downregulated and the cholesterol efflux capacity decreased [64, 65]. Promoting the expression of ABCA1 and ABCG1 can potentially inhibit the conversion of monocyte-derived macrophages into foam cells which contributes to preventing the formation and progression of atherosclerotic plaque. In animal models, Vasamsetti et al. [66] found metformin inhibits angiotensin II-induced lipid deposition in macrophages and reduces the formation of atherosclerotic plaques. In vitro experiments found that metformin inhibits monocytes differentiate into macrophages through the AMPK-STATA3 pathway [67]. Li et al. [68] found that metformin can upregulate the expression of ABCG1 in murine macrophages. Our previous study also confirmed that metformin could attenuate atherosclerosis by increasing the cholesterol efflux capacity of macrophages [33]. We also hypothesize that metformin may promote cholesterol efflux in macrophages by up-regulating FGF21 expression [69].

Conclusion

Metformin has been widely used as an anti-diabetic drug to treat patients with DM. Its cardioprotective role is being increasingly realized beyond its glucose lowering effect, although there may be some overlap of these two properties in the systemic cardioprotective effects. However, the anti-atherosclerotic effects of metformin, independent of its glycemic control remain unclear and is an area of active research. Evidence backing the pleiotropic effects of metformin in reducing CVD-related events necessitates further exploration with regard to the mechanism of drug action in various tissue compartments. The recent evidence pointing towards its therapeutic benefit in heart failure with persevered ejection fraction in clinical and preclinical studies underlines the need to explore the breadth of the pleiotropic systemic effects of metformin [70]. Recent study also reported that metformin offers therapeutic benefit during heart failure with preserved ejection fraction by lowering titin-based passive stiffness in mice model [71], is associated with improved survival and decreased incidence of adverse cardiac events in peripheral arterial disease patients [72] and with a lower below-the-knee arterial calcification score [73]. Moreover, metformin is able to prevent cardiac dysfunction in a murine model of adult congenital heart disease [70]. A proper understanding of these pleotropic effects will allow us to tailor the dose of the drug and remain abreast about its potential side effects in patients receiving them. Apart from their use in DM patients, its role in primary prevention of cardiovascular outcomes in ‘at-risk’ population, akin to statins, requires further exploration. Prospective population studies and randomized clinical trials need to be conducted to identify will allow us to identify a subset of patients who may benefit from early administration of metformin. This will further aid in disease surveillance and intervention through enhancement of primary and secondary prevention of CVD.

Abbreviations

ABCA1:

ATP-binding cassette transporter A1

ASCVD:

atherosclerotic cardiovascular disease

CAD:

coronary artery disease

CAMERA:

Carotid Atherosclerosis: MEtformin for insulin ResistAnce

DM:

diabetes mellitus

MACE:

major adverse cardiovascular events

PTCA:

percutaneous transluminal coronary angioplasty

REMOVAL:

REversing with MetfOrmin Vascular Adverse Lesions

SPREAD-DIMCAD:

study on the prognosis and effect of antidiabetic drugs on type 2 diabetes mellitus with coronary artery disease

TC:

total cholesterol

T2DM:

type 2 diabetes mellitus

TG:

triglyceride

VLDL:

very low-density lipoprotein

CIMT:

carotid intima-media thickness

UKPDS:

UK Protective Diabetes Study

VSMCs:

vascular smooth muscle cells

References

  1. 1.

    Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–492.

  2. 2.

    Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SS, Blumenthal RS. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2018. https://doi.org/10.1016/j.jacc.2018.11.005.

  3. 3.

    Webster MW, Scott RS. What cardiologists need to know about diabetes. Lancet. 1997;350(Suppl 1):SI23–8.

  4. 4.

    Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789.

  5. 5.

    Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313(1):37–44.

  6. 6.

    Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1):150.

  7. 7.

    Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85.

  8. 8.

    Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.

  9. 9.

    Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740–51.

  10. 10.

    Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegiani S, Turco S, Velussi M, Ferrannini E, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30(5):1241–7.

  11. 11.

    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65.

  12. 12.

    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.

  13. 13.

    Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, Stehouwer CD. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616–25.

  14. 14.

    Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, Kosugi K, Hori M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47(11):1906–13.

  15. 15.

    Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–8.

  16. 16.

    Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–11.

  17. 17.

    Petrie JR, Chaturvedi N, Ford I, Hramiak I, Hughes AD, Jenkins AJ, Klein BE, Klein R, Ooi TC, Rossing P, et al. Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. Diabetes Obes Metab. 2017;19(4):509–16.

  18. 18.

    Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597–609.

  19. 19.

    Lunder M, Janic M, Japelj M, Juretic A, Janez A, Sabovic M. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):153.

  20. 20.

    Chan CW, Yu CL, Lin JC, Hsieh YC, Lin CC, Hung CY, Li CH, Liao YC, Lo CP, Huang JL, et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol. 2018;17(1):20.

  21. 21.

    Dore FJ, Domingues CC, Ahmadi N, Kundu N, Kropotova Y, Houston S, Rouphael C, Mammadova A, Witkin L, Khiyami A, et al. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Cardiovasc Diabetol. 2018;17(1):65.

  22. 22.

    Younis A, Eskenazi D, Goldkorn R, Leor J, Naftali-Shani N, Fisman EZ, Tenenbaum A, Goldenberg I, Klempfner R. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ss in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovasc Diabetol. 2017;16(1):69.

  23. 23.

    Gillani SW, Sulaiman SAS, Abdul MIM, Baig MR. Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial. Cardiovasc Diabetol. 2017;16(1):103.

  24. 24.

    Hanem LGE, Salvesen O, Juliusson PB, Carlsen SM, Nossum MCF, Vaage MO, Odegard R, Vanky E. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019;3(3):166–74.

  25. 25.

    Chen XM, Zhang WQ, Tian Y, Wang LF, Chen CC, Qiu CM. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):53.

  26. 26.

    Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM, Sattar N. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2006;48(5):956–63.

  27. 27.

    Meaney E, Vela A, Samaniego V, Meaney A, Asbun J, Zempoalteca JC, Elisa ZN, Emma MN, Guzman M, Hicks J, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol. 2008;35(8):895–903.

  28. 28.

    Preiss D, Lloyd SM, Ford I, McMurray JJ, Holman RR, Welsh P, Fisher M, Packard CJ, Sattar N. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(2):116–24.

  29. 29.

    Sirtori CR, Catapano A, Ghiselli GC, Innocenti AL, Rodriguez J. Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits. Atherosclerosis. 1977;26(1):79–89.

  30. 30.

    Li SN, Wang X, Zeng QT, Feng YB, Cheng X, Mao XB, Wang TH, Deng HP. Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart Vessels. 2009;24(6):446–53.

  31. 31.

    Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei B, Alexander RW. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001202.

  32. 32.

    Cai Z, Ding Y, Zhang M, Lu Q, Wu S, Zhu H, Song P, Zou MH. Ablation of adenosine monophosphate-activated protein kinase alpha1 in vascular smooth muscle cells promotes diet-induced atherosclerotic calcification in vivo. Circ Res. 2016;119(3):422–33.

  33. 33.

    Luo F, Guo Y, Ruan GY, Long JK, Zheng XL, Xia Q, Zhao SP, Peng DQ, Fang ZF, Li XP. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Sci Rep. 2017;7(1):2169.

  34. 34.

    de Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, Bottino D, Bouskela E. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care. 2006;29(5):1083–9.

  35. 35.

    Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I, Pfeifer M. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159(4):399–406.

  36. 36.

    O’Hora TR, Markos F, Wiernsperger NF, Noble MI. Metformin causes nitric oxide-mediated dilatation in a shorter time than insulin in the iliac artery of the anesthetized pig. J Cardiovasc Pharmacol. 2012;59(2):182–7.

  37. 37.

    Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55(2):496–505.

  38. 38.

    Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S, Choi HC, Zou MH. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 2010;121(6):792–803.

  39. 39.

    Eriksson L, Nystrom T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovasc Diabetol. 2014;13:152.

  40. 40.

    Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, et al. Atherosclerotic vascular disease conference: writing group III: pathophysiology. Circulation. 2004;109(21):2617–25.

  41. 41.

    Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852–66.

  42. 42.

    Song P, Zhou Y, Coughlan KA, Dai X, Xu H, Viollet B, Zou MH. Adenosine monophosphate-activated protein kinase-alpha2 deficiency promotes vascular smooth muscle cell migration via S-phase kinase-associated protein 2 upregulation and E-cadherin downregulation. Arterioscler Thromb Vasc Biol. 2013;33(12):2800–9.

  43. 43.

    Ding Y, Zhang M, Zhang W, Lu Q, Cai Z, Song P, Okon IS, Xiao L, Zou MH. AMP-Activated protein kinase alpha 2 deletion induces VSMC phenotypic switching and reduces features of atherosclerotic plaque stability. Circ Res. 2016;119(6):718–30.

  44. 44.

    Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.

  45. 45.

    Xu T, Brandmaier S, Messias AC, Herder C, Draisma HH, Demirkan A, Yu Z, Ried JS, Haller T, Heier M, et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015;38(10):1858–67.

  46. 46.

    Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48–60.

  47. 47.

    Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93.

  48. 48.

    Fadini GP, Iori E, Marescotti MC, de Kreutzenberg SV, Avogaro A. Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients. Atherosclerosis. 2014;235(2):415–7.

  49. 49.

    Kubota M, Nakanishi S, Hirano M, Maeda S, Yoneda M, Awaya T, Yamane K, Kohno N. Relationship between serum cholesterol efflux capacity and glucose intolerance in Japanese-Americans. J Atheroscler Thromb. 2014;21(10):1087–97.

  50. 50.

    Goldberg RB, Temprosa M, Mele L, Orchard T, Mather K, Bray G, Horton E, Kitabchi A, Krakoff J, Marcovina S, et al. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism. 2016;65(5):764–75.

  51. 51.

    Matsuki K, Tamasawa N, Yamashita M, Tanabe J, Murakami H, Matsui J, Imaizumi T, Satoh K, Suda T. Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis. 2009;206(2):434–8.

  52. 52.

    Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–61.

  53. 53.

    Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74.

  54. 54.

    Dewey FE, Gusarova V, O’Dushlaine C, Gottesman O, Trejos J, Hunt C, Van Hout CV, Habegger L, Buckler D, Lai KM, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–33.

  55. 55.

    Peng J, Luo F, Ruan G, Peng R, Li X. Hypertriglyceridemia and atherosclerosis. Lipids Health Dis. 2017;16(1):233.

  56. 56.

    Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, Lombes M, Princen HM, Havekes LM, Rensen PC, Guigas B. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes. 2014;63(3):880–91.

  57. 57.

    Li R, Chen LZ, Zhao W, Zhao SP, Huang XS. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway. Biochem Biophys Res Commun. 2016;478(3):1173–8.

  58. 58.

    Luo F, Guo Y, Ruan GY, Peng R, Li XP. Estrogen lowers triglyceride via regulating hepatic APOA5 expression. Lipids Health Dis. 2017;16(1):72.

  59. 59.

    Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256(1):1–14.

  60. 60.

    Legein B, Temmerman L, Biessen EA, Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci. 2013;70(20):3847–69.

  61. 61.

    Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611–7.

  62. 62.

    Kim J, Kwak HJ, Cha JY, Jeong YS, Rhee SD, Kim KR, Cheon HG. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J Biol Chem. 2014;289(33):23246–55.

  63. 63.

    Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47(6):1183–8.

  64. 64.

    Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta. 2013;424:245–52.

  65. 65.

    Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–55.

  66. 66.

    Yang Q, Yuan H, Chen M, Qu J, Wang H, Yu B, Chen J, Sun S, Tang X, Ren W. Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits. Life Sci. 2018;198:56–64.

  67. 67.

    Vasamsetti SB, Karnewar S, Kanugula AK, Thatipalli AR, Kumar JM, Kotamraju S. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015;64(6):2028–41.

  68. 68.

    Li D, Wang D, Wang Y, Ling W, Feng X, Xia M. Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem. 2010;285(43):33499–509.

  69. 69.

    Luo F, Guo Y, Ruan G, Li X. Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism. Lipids Health Dis. 2016;15:109.

  70. 70.

    Wilmanns JC, Pandey R, Hon O, Chandran A, Schilling JM, Forte E, Wu Q, Cagnone G, Bais P, Philip V, et al. Metformin intervention prevents cardiac dysfunction in a murine model of adult congenital heart disease. Mol Metab. 2019;20:102–14.

  71. 71.

    Slater RE, Strom JG, Methawasin M, Liss M, Gotthardt M, Sweitzer N, Granzier HL. Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance. J Gen Physiol. 2019;151(1):42–52.

  72. 72.

    Khan SZ, Rivero M, Nader ND, Cherr GS, Harris LM, Dryjski ML, Dosluoglu HH. Metformin is associated with improved survival and decreased cardiac events with no impact on patency and limb salvage after revascularization for peripheral arterial disease. Ann Vasc Surg. 2019;55:63–77.

  73. 73.

    Mary A, Hartemann A, Liabeuf S, Aubert CE, Kemel S, Salem JE, Cluzel P, Lenglet A, Massy ZA, Lalau JD, et al. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16(1):24.

Download references

Authors’ contributions

ZF, XL and FL conceived the idea; FL and JC wrote the manuscript; AD and PW collected and read the literature and revised the article; ZF, XL read through and corrected the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

This work was supported by the grants from Hunan Provincial Innovation Foundation for Postgraduate (No. CX2018B068, Recipient: Fei Luo), Hunan Provincial Natural Science Foundation of China (No. 2018JJ2587, Recipient: Zhenfei Fang) and the National Natural Science Foundation of China (No. 81570267, Recipient: Zhenfei Fang, No. 31670816, Recipient: Xiangping Li).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Affiliations

  1. Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    • Fei Luo
    • , Panyun Wu
    • , Xiangping Li
    •  & Zhenfei Fang

  2. Departments of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA

    • Avash Das

  3. Department of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    • Jingfei Chen

Authors

  1. Search for Fei Luo in:

  2. Search for Avash Das in:

  3. Search for Jingfei Chen in:

  4. Search for Panyun Wu in:

  5. Search for Xiangping Li in:

  6. Search for Zhenfei Fang in:

Corresponding authors

Correspondence to Xiangping Li or Zhenfei Fang.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Metformin
  • Diabetes mellitus
  • Coronary artery disease
  • Atherosclerosis

Cardiovascular Diabetology

ISSN: 1475-2840

Contact us